Discovery calls for B2B SaaS founders for healthcare and life sciences in the DACH region
A founder-first breakdown of discovery calls — the parts you have to own personally, the parts you can delegate, and the traps that eat the first 18 months. Written for commercial leaders at healthtech, medtech, and life-sciences companies in the DACH region.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the DACH region. In this market, DACH buyers reward rigour, documentation, and long-cycle trust — not urgency-led campaigns, so the way you install discovery calls has to be shaped to that reality from day one.
If you are a B2B SaaS founder still under $5m ARR, discovery calls is not something you delegate on day one. It is the 30 minutes that decide whether a deal exists at all, and until it works you cannot describe your business without hand-waving.
The founder value in discovery calls is that everything after discovery is downstream of what you learned in it. You bring context no hire can replicate — the reason you started the company, the exact objection you heard on call number seven, the phrase a customer used that finally clicked.
Own the strategy, the first 30 live cycles, and the weekly review. Delegate the tooling, the list building, and the reporting. Founders who invert that order end up hiring around a broken model.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the DACH region it is compounded by the fact that trust-building cycle length, not intent is what actually gates growth. Discovery calls is only useful here when it is pointed at both constraints at once.
Instrument discovery-to-opportunity conversion from day one — even if the number is embarrassing. You cannot debug what you do not measure, and every board meeting after Series A will start with this chart.
The founder trap in discovery calls is reading a script instead of running a diagnosis. It always looks reasonable at the time. Write the trap on a sticky note and stick it on your monitor.
The moment to hand off discovery calls is when you can predict the number two weeks out and defend the assumptions behind it. Not before. VP hires that arrive earlier tend to leave inside 14 months.
Founders who take discovery calls seriously in year one write category-defining companies in year three. The compounding is that stark.
Concretely for healthcare and life sciences in the DACH region: the healthcare teams that install this get past procurement instead of dying in it, and one properly-run DACH account survives leadership changes and compounds for years. That is the reason it is worth installing discovery calls deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Sales · healthcare · DACH — answered
- Does discovery calls work for healthcare and life sciences in the DACH region?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in the DACH region, DACH buyers reward rigour, documentation, and long-cycle trust — not urgency-led campaigns. The healthcare teams that install this get past procurement instead of dying in it.
- Should the founder personally run discovery calls?
- Yes, until you can predict the number two weeks out. Then hand off the ops and keep the strategy.
- When can I hire someone to own discovery calls?
- When the metric is legible, the operating rhythm is documented, and you would rather work on the next constraint.
- What is the founder-specific mistake with discovery calls?
- Reading a script instead of running a diagnosis — usually because the founder wants to move on before the model is proven.
- How much of my week should discovery calls take as a founder?
- Roughly a third for the first two quarters, dropping to a weekly review once the metric is stable.
- What is the DACH-specific pitfall when running discovery calls for healthcare?
- Importing a playbook that was built for another market. In the DACH region, DACH buyers reward rigour, documentation, and long-cycle trust — not urgency-led campaigns — the install has to reflect that.
Growth Broker editorial
Filed under sales · healthcare · dach